The Stroke Catheter That Barely Needs a Second Try

First-pass success is like landing a plane on the first approach instead of circling the airport three times in a thunderstorm. You get where you're going, but the journey is shorter, safer, and less likely to end badly.

The Safety Profile Looks Clean

In a field where shoving catheters into brain arteries is the job description, safety data is everything. Perfuze's numbers here are encouraging.

Symptomatic intracranial hemorrhage (brain bleeding that causes noticeable worsening) occurred in just 1.7% of patients. Intracranial dissection, where the catheter damages the artery wall, hit 1.1%. Both figures are within the range that stroke neurologists consider acceptable for this type of procedure.

The device itself was deliverable in 96% of cases, meaning the catheter reached the clot site nearly every time. For the majority of patients, the blockage sat in the M1 segment of the middle cerebral artery (62% of cases), which is the most common and arguably most critical location for large vessel occlusions. In that M1 subgroup, the first-pass success rate climbed even higher to 77%.

The Functional Outcomes Tell the Real Story

Getting a clot out is important, but what patients actually care about is whether they can walk, talk, and live independently afterward. The final mTICI ≥2c rate (essentially near-complete or complete reperfusion) was 85% in the per-protocol population, suggesting that when this catheter works, it really works.

Perfuze's Quiet Regulatory Chess Game

What makes Perfuze's story interesting beyond the clinical data is its regulatory strategy. The company has been executing a stepwise 510(k) approach, which is the FDA's faster pathway for devices that are substantially similar to something already on the market. No lengthy PMA (premarket approval) process required.

The timeline tells the story of a company methodically building its portfolio. It started with an access catheter clearance in February 2023, expanded to aspiration catheters in 2024 and 2025, then secured clearance for the full Millipede88 Aspiration Catheter in March 2026. Each clearance built on the last, like stacking blocks toward a complete thrombectomy system.

Perfuze has signaled plans for a limited U.S. market release at select comprehensive stroke centers, a smart move that lets the company build real-world evidence and clinician familiarity before going broad.

The Competitive Landscape Is About to Get Interesting

The global mechanical thrombectomy market is growing. Stryker, Medtronic, and Penumbra have dominated this space for years. Perfuze is walking into a crowded room, but it's carrying an impressive set of data.

The 89% reperfusion rate without rescue therapy and 61% first-pass effect put the Millipede88 squarely in the conversation with established competitors. Whether Perfuze can translate clinical performance into market share depends on several factors: reimbursement dynamics, physician adoption, and the company's ability to scale manufacturing from a limited launch.

The Bottom Line

Stroke care is a race against biology. Every minute without blood flow means more dead brain tissue, more disability, more lives altered permanently. Perfuze's MARRS trial suggests that its Millipede88 catheter can win that race on the first try more often than not, with a clean safety profile to boot.

The company still has a long road from limited release to widespread adoption. But in a field where the difference between independence and dependence can come down to a few minutes on the procedure table, a catheter that gets it right the first time is exactly the kind of innovation that matters.

The First New Blood Cancer Drug in 30 Years Just Got the Green Light

For nearly 30 years, patients with essential thrombocythemia had zero new FDA-approved treatments. PharmaEssentia's BESREMi just broke that streak with trial results that crushed the competition seven to one.